Table 4 Results of cost-effectiveness and cost-utility analyses
Analysis | Sample size | Outcome | Cost difference (€) | Effect difference | ICER | Distribution CE plane | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Â | PST | UC | Â | (95% CI) | (95%CI) | Â | NE | SE | SW | NW |
Multiply imputed analysis | 88 | 87 | HADS | −2062 (−4698 ; 359) | −0.2 (−3.7 ; 3.2) | 8676 | 2% | 55% | 40% | 3% |
|  | 88 | 87 | QALY* | −2062 (−4698 ; 359) | 0.03 (−0.02 ; 0.08) | −65045 | 4% | 88% | 7% | 1% |
Complete cases | 56 | 63 | HADS | −2715 (−5858 ; 77) | 0.02 (−2.3 ; 2.4) | −113112 | 1% | 48% | 49% | 2% |
|  | 53 | 59 | QALY* | −3085 (−6300 ; -171) | 0.04 (−0.01 ; 0.08) | −83380 | 2% | 94% | 4% | 0% |
NHS perspective†| 88 | 87 | HADS | −253 (−1149 ; 476) | −0.2 (−3.7 ; 3.2) | 1065 | 11% | 45% | 28% | 16% |
|  | 88 | 87 | QALY* | −253 (−1149 ; 476) | 0.03 (−0.02 ; 0.08) | −7984 | 23% | 69% | 4% | 4% |
Human capital approach | 88 | 87 | HADS | −2397 (−5427 ; 393) | −0.2 (−3.7 ; 3.2) | 10084 | 2% | 55% | 40% | 3% |
|  | 88 | 87 | QALY* | −2397 (−5427 ; 393) | 0.03 (−0.02 ; 0.08) | −75597 | 4% | 88% | 7% | 1% |
Training costs PST excluded | 88 | 87 | HADS | −2035 (5669 ; 1259) | −0.2 (−3.7 ; 3.2) | 8564 | 6% | 50% | 38% | 6% |
|  | 88 | 87 | QALY* | −2035 (5669 ; 1259) | 0.03 (−0.02 ; 0.08) | −64198 | 11% | 81% | 7% | 1% |
Per protocol analysis | 41 | 87 | HADS | −3220 (−5744 ; -725) | 1.5 (−1.5 ; 4.4) | −2943 | 0% | 16% | 84% | 0% |
|  | 41 | 87 | QALY* | −3220 (−5744 ; -725) | 0.03 (−0.03 ; 0.09) | −137279 | 0% | 90% | 10% | 0% |
Observed outliers excluded | 88 | 84 | HADS | −1090 (−3492 ; 1175) | −0.3 (−3.8 ; 3.3) | 4297 | 7% | 49% | 33% | 11% |
|  | 88 | 84 | QALY* | −1090 (−3492 ; 1175) | 0.03 (−0.02 ; 0.08) | −34498 | 15% | 77% | 5% | 3% |